期刊文献+

雾化吸入伊洛前列素对肺动脉高压患者右心室功能的影响 被引量:3

Effects of inhaled aerosolized iloprost in adult patients with pulmonary arterial hypertension on right heart functions
原文传递
导出
摘要 目的探讨雾化吸入伊洛前列素对肺动脉高压患者右心室功能的影响。方法2010年1月至2010年12月于北京协和医院住院的30例肺动脉高压患者进行右心导管及超声心动图检查获得基线数据后雾化吸入伊洛前列素20μg进行血管扩张试验,吸入结束后即刻复测血流动力学及超声心动图,评估吸入药物前后右心功能的变化。结果所有患者吸入伊洛前列素后肺动脉平均压及肺循环阻力明显降低[(42.5±9.6)mmHg比(34.4±11.9)mmHg,P〈0.01;(9.6±5.7)Wood单位比(7.1±4.8)Wood单位,P〈0.001)],右心室侧壁三尖瓣环收缩期速度峰值(TASm)明显升高[(10.7±2.1)cm/s比(11.9±2.5)cm/s,P〈0.01],急性血管扩张试验阳性患者基线TASm显著高于阴性组(12.0±2.2)cm/s比(10.1±1.8)cm/s,P=0.01),急性血管扩张试验阴性组吸入伊洛前列素后TASm显著升高[(10.1±1.8)cm/s比(11.64-2.3)cm/s,P〈0.01],差异无统计学意义(P〉0.05)。结论吸入伊洛前列素可显著降低肺动脉高压患者的肺动脉压及肺循环阻力,并改善右心室收缩功能。血管扩张试验阴性的患者与阳性的患者相比右心室功能受损更为严重,吸入伊洛前列素后右心室功能的改善更为明显。 Objective To explore the immediate effects of inhaled aerosolized iloprost on fight heart function in adult patients with pulmonary arterial hypertension (PAH). Methods A total of 30 PAH patients were recruited. Right heart catheterization and echocardiography were performed before and immediately after the inhalation of iloprost (20 μg ). Results After inhalation, the values of mean pulmonary artery pressure (PAPm) and pulmonary vascular resistances (PVR) decreased markedly(42. 5 ± 9.6 to 34. 4 ± 11.9 mm Hg, P 〈0.001 ; 9. 6 ±5.7 Wood unit to 7.1 ±4. 8 Wood unit, P 〈0. 001). And the value of tricuspid annular systolic motion peak velocity (TASm) increased markedly [ ( 10. 7 ± 2. 1 ) cm/s vs ( 11.9 ± 2. 5 ) cm/s, P 〈 0. 01 ]. The baseline level of TASm was higher in acute responders than non-responders [ ( 12. 0 ± 2.2) cm/s vs ( 10. 1 ± 1.8 ) era/s, P = 0. 01 ] and TASm increased markedly after inhalation in non-responders [ ( 10. 1 ± 1.8 ) cm/s vs ( 11.6 ± 2. 3 ) cm/s, P 〈 0.01 ]. Conclusion The inhalation of iloprost decreases the levels of PAPm and PVR and improve fight heart functions in adult PAH patients. For non-responders, fight heart function is worse and more benefits may be achieved after the inhalation of iloprost.
出处 《中华医学杂志》 CAS CSCD 北大核心 2011年第40期2832-2836,共5页 National Medical Journal of China
基金 基金项目:国家“十一五”科技支撑计划课题(2006BAI01A07,2008BAI59B02) 国家自然科学基金(81072485,81071300) 中华医学会临床医学科研专项资金(08010270105)
关键词 高血压 肺性 心室功能 伊洛前列素 Hypertension, pulmonary Ventricular function, fight Inhalation
  • 相关文献

参考文献13

  • 1Thenappan T, Shah S J, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J,2007, 30:1103-1110.
  • 2Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension : the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J,2009, 30:2493-2537.
  • 3Olschewski H, Simonneau G, Gali~ N, et al. Inhaled iloprost for severe pulmonary hypertension . N Engl J Med, 2002,347 : 322- 329.
  • 4Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults : a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr,2010, 23:685-713.
  • 5Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, aprostacyclin analogue. N Engl J Med,2000,342 : 1866 - 1870.
  • 6Olschewski H, Nikkho S, Behr J, et al. Long-term survival in patients with pulmonary hypertension inhaling iloprost (AIR-2 study). Respir Med,2010,104:731-740.
  • 7Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol,2000,35:176-182.
  • 8Olschewski H, Rohde B, Behr J, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest, 2003, 124 : 1294 -1304.
  • 9Meluzin J, Spinarova L, Bakala J, imaging of the velocity of tricuspid et al. Pulsed Doppler tissue annular systolic motion. EurHeart J,2001,22:340-348.
  • 10Horton KD, Meece RW, Hill JC. Assessment of the right ventricle by eehocardiography : a primer for cardiac sonographers. J Am Soc Echocardiogr,2009 ,22 :776 -792.

同被引文献29

  • 1Galie N, Manes A, Negro L, et al. A recta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J, 2009, 30: 394-403.
  • 2McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation, 2002, 106 : 1477-1482.
  • 3Barst RJ. Recent advances in the treatment of pediatric pulmonary artery hypertension. Pedlatr Clin North Am, 1999, 46: 331-345.
  • 4McLaughlin VV, Sithon O, Badesch DB, et al. Survival with first- line bosentan in patients with primary pulmonary hypertension. Eur Respir J, 2005, 25 : 244-249.
  • 5Galie N, Ghofrani HA, Torbicki A, et al. Sildenalil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 2005, 353 : 2148-2157.
  • 6Gomberg-Maifland M, Dufton C, Oudiz RJ. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol, 2011,57: 1053-1061.
  • 7Macehia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J, 2007, 153 : 1037- 1047.
  • 8Galie N,Torhicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension : the task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology[J]. Eur Heart J, 2004,25: 2243-2278.
  • 9Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guiddines for the diagnosis and management of heart failure in adults: a report of the American College of Cardialogy Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation [J].J Am Coll Cardio1,2009,53 ( 15 ) : el -e90.
  • 10Haddad F, Doyle R, Murphy D J, et al. Right ventrieular function in cardiovascular disease part ]I: pathophysiology, clinical importance, and management of right ventricular failure [ J ]. Circulation ,2008,117 ( 13 ) : 1717-1731.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部